Comparative Pharmacology
Head-to-head clinical analysis: BOSUTINIB versus NERATINIB MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSUTINIB versus NERATINIB MALEATE.
BOSUTINIB vs NERATINIB MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a tyrosine kinase inhibitor that inhibits the BCR-ABL kinase, including many imatinib-resistant mutations, and Src family kinases.
Irreversible inhibitor of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) tyrosine kinases, leading to inhibition of downstream signaling pathways and tumor cell proliferation.
400 mg orally once daily with food.
240 mg (6 tablets of 40 mg) orally once daily with food, continuously until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life approximately 33 hours (range 22-60 hr) after oral administration, supporting once-daily dosing.
Clinical Note
moderateBosutinib + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Bosutinib."
Clinical Note
moderateBosutinib + Digitoxin
"Bosutinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateBosutinib + Deslanoside
"Bosutinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateBosutinib + Acetyldigitoxin
"Bosutinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life is approximately 7–17 hours (mean 12 hours); this supports twice-daily dosing. Steady-state is achieved within 7 days.
Primarily fecal (approx. 68% as unchanged drug and metabolites) and renal (approx. 25%, with <0.2% as unchanged drug in urine).
Primarily fecal (approximately 97% of the administered dose recovered in feces as unchanged drug and metabolites); renal excretion is minimal (approximately 1% of the dose recovered in urine).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor